Business, energy, technology, markets and global industry news from Business News Today

Lunit

PharmaDeviceNews Lunit
Representative image of circular DNA analysis in a modern genetics research lab, reflecting Phinomics’ focus on explainable artificial intelligence, multi-omic cancer research and oncology biomarker discovery.
Pharma & Biotech

Can Lunit’s AI pathology partnership accelerate cancer biomarker discovery?

Lunit will integrate its SCOPE artificial intelligence pathology platform into Discovery Life Sciences' tissue analysis services, expanding access to standardized biomarker research. The collaboration strengthens Lunit's precision oncology strategy, although financial terms, client adoption and new clinical validation outcomes remain undisclosed.

Read More
Features & Analysis

Is AI finally ready to close the equity gap in breast cancer screening in the United States and beyond?

The rapid progress of artificial intelligence in medical imaging is creating fresh optimism among healthcare leaders seeking to close the persistent equity gap in breast cancer screening. The regulatory push by Lunit, a Seoul-based AI diagnostics firm, for its Lunit INSIGHT Risk model, which estimates a woman’s five-year breast cancer risk directly from mammogram images,

Read More